Emergence of the Novel Sixth *Candida auris* Clade VI in Bangladesh

Tahsin Khan[1], Naimul Islam Faysal[1], Md Mobarok Hossain[1], Syeda Mah-E-Muneer[2], Arefeen Haider[1], Shovan Basak Moon[1], Debashis Sen[3], Dilruba Ahmed[3], Lindsay A. Parnell[4], Mohammad Jubair[1], Nancy A. Chow[4], Fahmida Chowdhury[2], Mustafizur Rahman[1,2]

[1]Genome Centre, Infectious Diseases Division, icddr,b, Mohakhali, Dhaka-1212, Bangladesh

[2]Emerging Infections, Infectious Diseases Division, icddr,b, Mohakhali, Dhaka-1212, Bangladesh

[3]Mycology Laboratory, icddr,b, Mohakhali, Dhaka-1212, Bangladesh

[4]Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA

Correspondence to:

Mustafizur Rahman, PhD, 68 Shaheed Tajuddin Ahmed Sarani, Dhaka 1212, Bangladesh; mustafizur@icddrb.org; Telephone number: +880 2 9840523-32

ABSTRACT

Candida auris, initially identified in 2009, has rapidly become a critical concern due to its antifungal resistance and significant mortality rates in healthcare-associated outbreaks. To date, whole-genome sequencing (WGS) has identified five unique clades of *C. auris*, with some strains displaying resistance to all primary antifungal drug classes. In this study, we presented the first WGS analysis of *C. auris* from Bangladesh, describing its origins, transmission dynamics, and antifungal susceptibility testing (AFST) profile. Ten *C. auris* isolates collected from hospital settings in Bangladesh were initially identified by CHROMagar™ Candida Plus, followed by VITEK®2 system and later sequenced using Illumina NextSeq 550 system.

Reference-based phylogenetic analysis and variant calling pipelines were used to classify the isolates in different clades. All isolates aligned ~90% with the Clade I *C. auris* B11205 reference genome. Of the ten isolates, eight clustered with Clade I isolates, highlighting a South Asian lineage prevalent in Bangladesh. Remarkably, the remaining two isolates formed a distinct cluster, exhibiting >42,447 SNP differences compared to their closest Clade IV counterparts. This significant variation corroborates the emergence of a sixth clade (Clade VI) of *C. auris* in Bangladesh, with potential for international transmission. AFST results showed that 80% of the *C. auris* isolates were resistant to fluconazole and voriconazole, whereas Clade VI isolates were susceptible to azoles, echinocandins, and polyenes classes. Genomic sequencing revealed *ERG11*_Y132F mutation conferring azole resistance while *FCY1*_S70R mutation found inconsequential in describing 5-flucytosine resistance. Our study underscores the pressing need for comprehensive genomic surveillance in Bangladesh to better understand the emergence, transmission dynamics, and resistance profiles of *C. auris* infections. Unveiling the discovery of a sixth clade (Clade VI) accentuates the indispensable role of advanced sequencing methodologies.

IMPORTANCE

Candida auris is a nosocomial fungal pathogen which is commonly misidentified as other *Candida* species. Since its emergence in 2009, this multi-drug resistant fungus has become one of the five urgent antimicrobial threat by 2019. Whole Genome Sequencing (WGS) has proven to be the most accurate identification technique of *C. auris* which also played a crucial role in the initial discovery of this pathogen. WGS analysis of *C. auris* has revealed five distinct clades where isolates of each clade differ among themselves based on pathogenicity, colonization, infection mechanism as well as other phenotypic characteristics. In Bangladesh, *C. auris* was 1st reported in 2019 from clinical samples of a large hospital of Dhaka city. To understand the

51 origin, transmission dynamics and antifungal resistance profile of *C. auris* isolates circulating
52 in Bangladesh, we conducted WGS based surveillance study on two of the largest hospital
53 settings in Dhaka, Bangladesh.
54
55 **INTRODUCTION**
56 *Candida auris*, an emerging multidrug-resistant pathogen, imposes a serious threat to global
57 public health owing to its high virulence and transmissibility in hospital settings [1]. Since the
58 first report in 2009 in Japan, this nosocomial pathogen has already been reported in over 50
59 countries, colonizes human skin and hospital environments, and causes invasive candidiasis,
60 especially in critically ill and immunosuppressed patients [2-4]. Patients with *C. auris* infection
61 or colonization frequently exhibit other underlying health conditions and comorbidities, such
62 as diabetes, cardiovascular diseases, liver diseases, chronic or acute kidney failure, solid tumor
63 or malignancies [5].
64 Whole-genome sequencing (WGS) and matrix-assisted laser desorption ionization–time of
65 flight (MALDI-TOF MS) platforms are the best-suited options to correctly identify *C. auris*
66 [6]. Worldwide, WGS analysis has grouped *C. auris* into five distinct genotypic clades based
67 on 40,000 to >200,000 single nucleotide polymorphism (SNPs) such as Clade I (South Asia),
68 Clade II (East Asia), Clade III (Africa), Clade IV (South America), and Clade V (Iran) [3, 7,
69 8]. Though the reasons for the reported independent and simultaneous emergence in different
70 geographical regions are unknown, animal reservoirs and environmental changes are
71 speculated to accelerate this situation [9]. Each clade harbors highly related isolates due to local
72 transmission and clonal expansion within countries [10, 11]. However, analysis from molecular
73 epidemiological investigations, outbreaks, and individual cases also revealed genetic
74 complexity suggesting multiple introductions followed by local transmissions in different
75 countries [12].

76 Antifungal resistance seems to be clade specific [13]. Clade II isolates are generally more
77 susceptible to antifungal agents, whereas Clade I, III and IV are highly resistant [1, 8, 14]. Only
78 2/5 identified isolates of Clade V were found resistant to fluconazole but were susceptible to
79 triazoles, echinocandins, and amphotericin B [15, 16]. Nonetheless, antifungal resistances were
80 observed on all five clades to currently used antifungal drugs such as azoles (fluconazole,
81 voriconazole, itraconazole, and isavuconazole), polyenes (amphotericin B), echinocandins
82 (caspofungin, micafungin, and anidulafungin), and pyrimidine analogue flucytosine [11, 17-
83 19]. Genomic level inspections revealed clade-specific azole-resistant mutations in *ERG11*:
84 Y132F or K143R in Clade I, F126T/L in Clade III, Y132F in Clade IV, and Clade V [3, 7].
85 Numerous mechanisms responsible for antifungal resistance have been reported for *C. auris*,
86 such as echinocandin-resistant *FKS1*:S639/F/P/Y, and *FKS1*:S635Y/P mutations, 5-flucytosine
87 resistant *FCY1*:S70R, *FCY2*:M128fs (frameshift), *ADE17*:G45V and *FUR1*:1Δ33 [20, 21].
88 Resistance mechanisms for amphotericin B are not well documented; however, WGS analysis
89 has identified several nonsynonymous polymorphisms that might infer resistance [22].
90 Bangladesh (BD) is located in South Asia where fungal outbreaks have been widely reported
91 [23-25]. The first reported case of *C. auris* in Bangladesh was in 2019, whereas India and
92 Pakistan reported in 2013 and 2015 respectively [7, 26, 27]. Dutta et al., 2019 reported *C. auris*
93 infections in 19 patients that showed resistance to voriconazole (18/21), fluconazole (14/21),
94 and amphotericin B (5/21) [28]. A recent study that conducted AFST for major fungal
95 pathogens in different hospital settings in Bangladesh also reported *C. auris* resistance against
96 fluconazole (100%), itraconazole (100%), voriconazole (33.3%), and amphotericin B (100%)
97 [29]. Monitoring the circulating clades and observing the resistance pattern of *C. auris* is
98 crucial to prevent spread and transmission. Considering the absence of genomic surveillance
99 data for *C. auris* in Bangladesh, we conducted WGS analysis on 10 *C. auris* isolates collected
100 from intensive Care unit (ICU) and neonatal intensive care unit (NICU) patients from two

national hospitals in Bangladesh. We report the emergence of a sixth clade (Clade VI), circulating along with Clade I isolates in Bangladesh.

RESULTS

Patient Information.

Ten *C. auris* isolates representing eight ICU patients and two NICU patients were described in this study. Patients were admitted with various underlying health complications; none had candidemia (**File S1**). Among the patients, only one patient (101022) from ICU had previous travel history to the United Arab Emirates within one year of enrolment. Overall, 40% (4 patients from ICU) developed nosocomial colonization with *C. auris*, and none received any antifungal treatment since patients either expired or were discharged by the time the test result was released (Table 1).

TABLE 1: Patient metadata of sequenced *Candida auris* isolates.

WGS SNP Calling and Phylogeny Analysis: Emergence of a Novel Clade.

Whole genome-based SNP calling was performed to distinguish all BD isolates in different clades, incorporating a total of 25 *C. auris* isolates that represent the known five clades (**File S2**). Around 92.68% (SD ±1.17) reads of BD isolates mapped with the reference B11205 with an average GC content of 44.41% (SD ±0.15) (**File S3**). Phylogenetic analysis revealed that BD-ICU isolates (Sample ID 101019, 101008, 101009, 101022, 101077, 101082, 101101, and 101087) clustered closely with Clade I with a maximum SNP difference of 163 SNPs (Fig. 1, **File S4**). Notably, these isolates differed by only ≤17 SNPs from each other except isolates 101019 and 101022. The isolate (101022) collected from the ICU patient who traveled to UAE was separated by only 18 SNPs from the UAE_B14000 isolate. Isolate 101019 had the highest SNP differences with other Clade I BD-ICU isolates (87-102 SNPs). Within the Clade I

clusters, Clade I BD isolates had closer resemblance to UK_15B5 isolate (51-86 SNPs) than those from India (108-155 SNPs), Pakistan (109-148 SNPs) and New Jersey, USA (124-163). Interestingly, the BD-NICU isolates (102096, and 102170) clustered separately from all known clade isolates (Fig. 1). These two isolates differed by only 68 SNPs and were genetically distinct from all the clades by at least 42,447 single-nucleotide polymorphisms, and hence, formed a novel clade, Clade VI [7]. South American Clade (Clade IV) was the closest neighbor (>42,447 SNPs) for Clade VI, whereas the Iranian Clade (Clade V) was the most distant neighbor (>254,068 SNPs). To pinpoint the origin of this novel clade, we inquired the neonates' parents about any international travel history, but none had any in 2020 or before. The two neonates were born in different hospitals, but later they were transferred to the NICU of study hospital. It was unknown whether their parents were suffering from fungal colonization or infections; or whether these neonates acquired *C. auris* colonization during birth or from the previous hospitals. To investigate the emergence of this novel clade, phenotypic differences between the Clade I and Clade VI isolates were observed and are described in Table 2 (**Fig S1**).

TABLE 2: Phenotypic differences observed between BD Clade I and Clade VI isolates of *Candida auris* at different timelines (A) 24 hours (B) 48 hours and (C) 72 hours.

FIG 1. Phylogenetic tree based on SNPs of 35 *C. auris* isolates. (A) Representation of known five clades with novel Clade VI of *C. auris*. (B) Distances between Clade IV and novel Clade VI. All the BD isolates from our study are represented by dark blue color. Eight BD-ICU isolates clusters with reference isolate and 5 Clade I isolates from different countries. Two BD-NICU isolate (102096, and 102170) clusters together distinctly from other clades forming novel Clade VI. Isolate B11243 of Clade IV has the closest SNP distances from Clade VI

150 isolates. (C) Clade-wise heatmap of SNP distances among all *C. auris* isolates used in this
151 study.
152
153 **Molecular Resistance Mechanisms.**
154 All the BD isolates were screened for mutations associated with antifungal resistance. For
155 fluconazole and other triazole resistance, *ERG11, CDR1, TAC1B* and *MRR1A* gene mutations
156 were screened in several positions leading to increased MIC values. All BD-ICU isolates of
157 Clade I harbored *ERG11*_Y132F substitution. No mutations were detected in *CDR1, TAC1B*
158 and *MRR1A* genes. No known *FKS1* gene mutation was observed in BD-ICU isolates which is
159 reflected by susceptibility to caspofungin in AST results (Table 3). *FCY1*_S70R mutation
160 which confers 5-flucytocine resistance was detected in all BD-ICU isolates by genomic
161 analysis. No mutations in *ERG3* and *ERG6* genes were detected which could explain the
162 amphotericin B resistance in isolate 101022. Surprisingly, Clade VI isolates from BD-NICU
163 patients had no known mutations in any of the drug resistance genes (Table 3).
164
165 **TABLE 3**: Results of known mutation analysis and antifungal susceptibility test for azoles,
166 polyenes, and echinocandins.
167
168 **Antifungal Susceptibility Testing (AFST).**
169 Antifungal susceptibility testing was performed on all BD *C. auris* isolates against fluconazole,
170 voriconazole, caspofungin, and amphotericin B (Table 3). Based on U.S. CDC tentative
171 breakpoints, all BD-ICU isolates were highly resistant to fluconazole (MIC 256 mg/L) and
172 voriconazole (MIC 32 mg/L). Isolate 101022 collected from patient with recent travel history
173 to the United Arab Emirates additionally showed resistance to amphotericin B (MIC 2 mg/L)
174 along with fluconazole and voriconazole. No resistance was observed for caspofungin in BD-

175 ICU isolates. On the contrary, BD-NICU isolates representing Clade VI were susceptible to 3
176 major antifungal drug classes. However, BD-NICU isolate 102170 demonstrated resistance to
177 amphotericin B (MIC 2 mg/L). Only isolate 101019 of Clade I harboring *FCY1*_S70R mutation
178 showed resistance against 5-flucytosine in both disk diffusion and automated VITEK®2
179 methods, while other Clade I isolates showed sensitivity in both methods even though these
180 harbor the same mutation (Table 4). Mutational analysis on the resistance profile aligned with
181 the AFST results except for isolate 101022 and 102170; no known mutation was found that
182 confer amphotericin B resistance.
183
184 **TABLE 4:** Results of 5-flucytosine antifungal susceptibility test by disk diffusion and
185 VITEK®2 method.
186
187 **DISCUSSION**
188 *Candida auris,* first detected in Bangladesh in 2019, has emerged as a global multi-drug
189 resistant healthcare-associated pathogen [29]. WGS-based approach revealed the circulation of
190 Clade I lineages, and the emergence of a new Clade VI in Bangladesh. Six BD-ICU Clade I
191 isolates (101008, 101009, 101077, 101082, 101101, 101087) collected from adult patients, who
192 never traveled overseas, are phylogenetically closest to each other (SNPs range 3-17),
193 indicating the ongoing local and clonal transmission [12, 30]. The isolate 101022 from an ICU
194 patient who previously traveled to UAE and died after admission was only 18 SNPs different
195 than UAE_B14000, indicating possible Clade I transmission from UAE to Bangladesh.
196 The genome sequencing approach separated the clades of *C. auris* by tens of thousands of SNP
197 differences [7]. The ~42,447 SNPs difference of BD-NICU isolates (102096 and 102170)
198 indicate the emergence of the new clade, Clade VI, in Bangladesh. Though tracing was not
199 possible to identify the source of this nosocomial infection in neonates, it is evident that Clade

200 VI is circulating in Bangladesh. By the time of writing this manuscript, a preprint published by
201 a group of researchers from Singapore claimed the presence of a new clade separated by
202 >36,000 SNPs from all known five clades of *C. auris* [31]. These isolates namely isolate A
203 (LIMS ID F3485, Biosample SAMN36753178), Isolate B (LIMS ID F1580, Biosample
204 SAMN36753179), Isolate C (LIMS ID F0083, Biosample SAMN36753180), and 102096 from
205 our study (SRR24877248) were distinct by at least 70 SNPs [31]. Isolate C of the novel clade
206 was collected from the blood of a Bangladeshi patient in 2018, who was airlifted directly to
207 Singapore General Hospital to have treatment, and was initially classified as Clade IV [30].
208 The presence of candidemia in this patient indicates the undetected circulation of novel *C. auris*
209 clade in Bangladesh and a later transfer to Singapore in 2018 before the first detection of *C.*
210 *auris* in Bangladesh in 2019 [28]. It is surprising to note that even though Clade I and Clade
211 VI isolates are circulating in Bangladesh simultaneously, Clade VI isolates acquired no known
212 mutations and showed no phenotypic resistance. It is of utmost importance to conduct
213 nationwide genomic surveillance of prospectively collected *C. auris* isolates along with
214 archived isolates stored at different hospitals in Bangladesh to understand the origin and
215 transmission dynamics of Clade VI.
216 Clade I BD-ICU isolates showed the general trend of azole resistance for both mutational
217 (genotypic) and AFST (phenotypic) results against fluconazole and voriconazole [7].
218 Surprisingly, these isolates showed inconsistency for 5-flucytosine resistance pattern except
219 for isolate 101019. A similar observation was reported from a 29-year-old woman residing in
220 New Jersey, who was diagnosed with severe short bowel syndrome [20]. She underwent a
221 multi-visceral transplantation surgery and during her post-operative period of 72 days, the
222 patient developed refractory fungal peritonitis. Nineteen *C. auris* isolates were obtained from
223 the patient at various time intervals. While the initial 12 isolates collected within the initial 33
224 days demonstrated sensitivity to 5-flucytosine, the subsequent 7 isolates obtained between days

225 33 and 72 exhibited resistance to this antifungal agent. Genomic analysis of these isolates
226 revealed the presence of the *FCY1*_S70R mutation in all 19 isolates. The authors argued
227 *FCY1*_S70R mutation to be inconsequential in describing 5-flucytosine resistance. The
228 findings in our study reflected the discrepancy between *FCY1*_S70R mutation and resistance
229 pattern for Clade I isolates, strengthening the argument of inconsequential behavior of
230 *FCY1*_S70R mutation in describing the 5-flucytosine resistance. Two BD-NICU isolates
231 representing Clade VI neither exhibited resistance to any of the antifungals tested nor harbored
232 any known mutations conferring resistance. Active clinical surveillance, monitoring of clinical
233 symptoms, and extensive epidemiological investigation will accelerate understanding of the
234 significance of this newly discovered sixth clade of *C. auris*.
235
236 **LIMITATIONS**
237 Our study presents the WGS-based approach to detect the circulation of *C. auris* clades for the
238 first time in Bangladesh. The isolates sequenced in this study were collected from the archived
239 samples in 2021, as part of regular surveillance to monitor infections and colonization
240 associated with ICU/NICU admitted patients, tracing the contacts of *C. auris* positive cases
241 was not performed at that time. The small sample size in this study may not be the
242 representative picture of *C. auris* circulation in Bangladesh. Including a large sample size
243 would increase the chances of capturing other undetected clades circulating in Bangladesh.
244 Long-read sequencing would ensure the recovery of the nearly full genome and the
245 comprehensive genomic study on the antifungal resistance profile. Overall, our study
246 demonstrates the necessity of *C. auris* genomic surveillance to understand the transmission
247 dynamics, pathobiology and containment of this urgent antimicrobial-resistant threat in
248 Bangladesh.
249

250 **CONCLUSION**

251 We report the circulation of Clade I *C. auris* in Bangladesh along with the emergence of the
252 novel Clade VI detected patients in the ICU and NICU. Bangladesh remains the hub of this
253 novel clade since a Clade VI isolate was also found in the blood of a Bangladeshi patient
254 airlifted in Singapore in 2018. It is critical that we enforce nation-wide genomic surveillance
255 to better understand the emergence and transmission of this novel clade in Bangladesh.

256

257 **MATERIALS AND METHODS**

258 **Isolate Selection.**

259 From August-September 2021, as part of ongoing hospital surveillance, we identified a total of
260 60 *Candida auris* isolates and archived these isolates at the International Centre for Diarrhoeal
261 Disease Research, Bangladesh (icddr,b) Mycology Laboratory. Isolates were cultured from
262 skin swab samples from both axilla and groin for screening the patients admitted in the ICU
263 and NICU of two tertiary care hospitals (one public and one private). In addition to on-
264 admission screening sample, subsequent follow up samples were collected- after 72 hours of
265 admission and before shifting from ICU- from patients to identify nosocomial colonization.
266 [32]. Isolates from ICU patients were termed as BD-ICU, and isolates from NICU patients
267 were termed BD- NICU throughout the manuscript.

268 **DNA Extraction and Whole Genome Sequencing.**

269 Ten *C. auris* isolates were randomly selected and retrieved from −80°C storage and grown on
270 CHROMagar™ Candida Plus media for presumptive identification of *C. auris*. Pure *C. auris*
271 colonies were transferred from CHROMagar™ plate to SDA plate and incubated at 37^0C for
272 72 hours. Genomic DNA of the *C. auris* isolates was extracted using the Qiagen DNAeasy
273 Blood & Tissue Kit, and the Illumina DNA Prep kit (Illumina Inc., San Diego, California, USA)

274 was used for the construction of DNA libraries. Sequencing was performed on Illumina
275 NextSeq 550 platform with 2x150 bp cycles at icddr,b Genome Centre.

276 **Variant Calling and Phylogenetic Analysis.**

277 To investigate the origin and possible route of transmission of sequenced *C. auris* isolates from
278 Bangladesh, phylogenetic analysis was performed using the whole-genome sequences. A total
279 of 25 isolates representative of *C. auris* clades I – V were also included in this analysis (**File**
280 **S2**). Quality control, single nucleotide polymorphism (SNP) calling, and phylogenetic analysis
281 were performed using the reference-based pipeline, MycoSNP, v1.4
282 (https://github.com/CDCgov/mycosnp-nf) with default parameters and using assembly B11205
283 (Accession no. GCA_016772135.1) generated from an isolate from India [33]. In brief, the
284 MycoSNP workflow masks repetitive regions and indexes the reference genome in preparation
285 for read alignment and snp calling. Paired-end reads were trimmed and filtered for low quality
286 data. Samples, with at least 20X coverage and a % GC content between 42-47.5%, were used
287 for alignment to the reference genome using the BWA [34] and pre-processed for downstream
288 single-nucleotide polymorphism (SNP) analysis using GATK[35]. GATK *HaplotypeCaller*
289 function is used for haplotype calling the processed BAM files from each isolate. The ploidy
290 parameter for *C. auris* is set to haploid. *HaplotypeCaller* uses the PairHMM (Pair Hidden
291 Markov Models) algorithm and performs pairwise alignment. Then, the resulting individual
292 gVCF files are merged into a single multi-sample gVCF file by *CombineGVCFs* function.
293 Next, the *GenotypeGVCFs* function performs SNP calling from this single gVCF file which
294 results in a VCF file with all samples genotyped. GATK's *VariantFiltration* function was used
295 to filter SNP sites based on the QualityByDepth (QD), FisherStrand Score (FS) and
296 RMSMappingQuality (MQ) parameters using filtering expression: "QD < 2.0 || FS > 60.0 ||
297 MQ < 40.0". Additional customized SNP filters were applied based on parameters such as
298 Genotype Quality (GQ), allele depth (AD), and depth (DP) using following criterion: : GQ ≥

299 50, AD ≥ 80%, DP ≥ 10. The MycoSNP workflow recovered all SNP alleles from the VCF files
300 using a Python script "vcfSnpsToFasta.py" (https://github.com/broadinstitute/broad-
301 fungalgroup/tree/master/scripts/SNPs) to create an SNP alignment in multi-fasta format [33].
302 To construct Maximum Likelihood (ML) phylogenetic trees from SNP alignment, RAxML
303 v8.2.12 [36] was utilized with the Generalized Time-Reversible model and a Gamma
304 distribution (GTRGAMMA) to account for site-specific rate variation. Support for the ML
305 phylogenetic trees were evaluated through 1000 bootstrap replicates of the alignment. The
306 resulting trees were visualized using iTol v5.5 [37].

307 **Mutational Characterization.**

308 *De novo* assembly was performed using SPAdes v.3.15.5 to generate assemblies and assessed
309 with Quast v.5.5.0 [38, 39]. The assembly reports were summarized in **File S5** in the
310 supplemental material. A custom python script was generated to map *ERG11* (F126L, Y132F,
311 K143R, and F444L), *CDR1* (V704L), *TAC1B* (S611P) and *MRR1A* (N647T) for azole
312 resistance, *FCY1* (S70R) and *FUR1* (1Δ33, and F211I) for 5-flucytocine resistance and *FKS1*
313 (S639Y/P/F, and F635C) genes for echinocandin resistance. Since the molecular mechanism
314 of amphotericin B is not well established, we also investigated known mutations in *ERG3*
315 (S58T) and *ERG6* (G403T, and R97fs) genes involved in ergosterol biosynthetic pathways
316 which are postulated to confer amphotericin B resistance [14, 40].

317 **Antifungal Susceptibility Testing (AFST).**

318 To assess the resistance of *C. auris* to antifungals, antifungal susceptibility testing (AFST) was
319 performed using Gradient Diffusion Strips method or E-test (OFD-500-P03:
320 https://www.cdc.gov/fungal/lab-professionals/pdf/afst-yeasts-h.pdf) according to Clinical and
321 Laboratory Standards Institute (CLSI) guidelines [41]. The E-test gradient strips of
322 fluconazole, voriconazole, caspofungin, and amphotericin B was obtained from Biomerieux.
323 The reference number and lot number of corresponding anti-fungal strip are provided in **File**

324 **S6**. The fluconazole concentration gradient ranged from 256 to 0.016 µg/ml while for other
325 antifungals, it ranged from 32 to 0.002 µg/ml. The antifungals used in this study for AFST are
326 representative of 3 major classes of antifungals (azoles, echinocandins and polyenes). The
327 culture media used were Sabouraud dextrose agar (SDA; Becton Dickinson) and Roswell Park
328 Memorial Institute medium 1640 (RPMI-1640; Sigma–Aldrich). Currently, there are no
329 established minimum inhibition concentration (MIC) breakpoints for *C. auris.* CDC proposed
330 tentative breakpoints for fluconazole (≥ 32 mg/L), voriconazole (≥ 1mg/L), caspofungin (≥ 2
331 mg/L), anidulafungin (≥ 4 mg/L), micafungin (≥ 4 mg/L), amphotericin B (≥ 2 mg/L) and other
332 antifungals [7, 18, 42].
333 The *C. auris* isolates from this study were also tested for susceptibility to 5-flucytosine by disk
334 diffusion method outlined by CLSI-M60 guidelines [43]. The assays were performed using
335 fungal suspension adjusted to match the turbidity of a 0.5 McFarland standard. The antifungal
336 disk for Flucytosine (AFY) 10 µg was purchased from Liofilchem®, Italy**)**. Mueller Hinton II
337 Agar (MHA; BD), Sabouraud Dextrose Agar (SDA; BD) and Roswell Park Memorial Institute
338 Medium 1640 (RPMI-1640; Sigma–Aldrich) was used for preparation of media of the *C. auris*
339 isolates. The reference and lot number of corresponding agar and media are provided in **File**
340 **S6**. The disks were placed on to the inoculum media and the plates were incubated at
341 $35^0C(\pm 2^0C)$ for 18-24 hours. After 24 hours, the plates were examined and the zones of
342 inhibition diameter (ZOD) around the discs were measured in millimeters (mm). The inhibition
343 zone diameters (mm) were interpreted as Susceptible (S), Intermediate (I) and Resistant (R)
344 based on established clinical breakpoints provided by CLSI. Susceptibility to 5-flucytosine was
345 also tested via automated VITEK®2 system using an AST-YS09 card as per the manufacturer's
346 instructions. The time and temperature of incubation was similar to disk diffusion assay
347 $(18 - 24\ hours\ at\ 35 \pm 2^0C)$ but the results were expressed as MICs. The MIC calling range
348 was 1 to 64 mg/L for 5-flucytosine. Since the VITEK®2 system lacks species-specific MICs

349 for *C. auris*, the species was modified to different *Candida* spp. to obtain MICs for *C. auris*
350 isolates. Notably, the MIC values remained consistent irrespective of the species assigned when
351 retrieving MIC data for *C. auris* across all drugs. As *C. duobushaemulonii* closely related to *C.*
352 *auris* and belongs to the *C. haemulonii* complex , analysis was based on MICs retrieved from
353 this species [44, 45].
354
355 **Ethical approval.**
356 The study was approved by icddr,b Research Review Committee and Ethical Review
357 Committee. The approval protocol number was PR-20122. All patients participated in this
358 study gave written informed consent for donating the samples.
359 **Data availability.**
360 The sequencing data sets generated during this study are available in the Sequence Read
361 Archive repository under projects PRJNA981511.
362 **ACKNOWLEDGMENTS**
363 The study was funded by Centre for Disease Control and Prevention, Atlanta, USA, through
364 cooperative agreement. We also gratefully acknowledge icddr,b core donors (Govt. of
365 Bangladesh and Canada) for their unrestricted support and commitment to icddr,b's research
366 efforts.
367
368 Conceptualization, T.K., N.I.F., M.J., F.C., and M.R.; data curation, T.K., N.I.F., M.M.H., S.M.,
369 A.H., and D.S.; formal analysis, T.K., N.I.F., M.M.H., A.H., S.B.M., D.S., and L.A.P.;
370 investigation, T.K., N.I.F., S.M., DA, M.J., N.A.C., F.C., and M.R.; methodology, T.K., N.I.F.,
371 M.M.H., A.H., S.B.M., DA, L.A.P., and M.J.; validation, T.K., N.I.F., A.H., S.B.M., D.S., DA,
372 L.A.P., M.J., F.C., and M.R.; supervision, F.C., and M.R.; visualization, T.K., M.M.H., L.A.P.,

and N.A.C.; writing - original draft, T.K., N.I.F., and M.R.; writing -review & editing, T.K., N.I.F., M.M.H., S.M., A.H., S.B.M., D.S., DA, L.A.P., M.J., N.A.C., F.C., and M.R.

Disclaimer: The findings and conclusions of this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control (CDC). The Sample IDs and Sequencing IDs used in this manuscript were randomly assigned, did not correspond to any of the hospital generated original IDs and were not disclosed to anyone outside the research group, not even to hospital staff or patients themselves.

Supplemental Material

Fig S1: Phenotypic differences observed between BD Clade I and Clade VI isolates of *Candida auris* at different timelines (A) 24 hours (B) 48 hours and (C) 72 hours.

File S1: Patient metadata of BD *Candida auris* isolates.

File S2: *Candida auris* isolates used in this representing known five clades.

File S3: Quality metrices of BD *Candida auris* isolates generated by MycoSNP v1.4.

File S4: SNP distances generated by MycoSNP v1.4 for all *Candida auris* isolates in this study.

File S5: Assembly metrices of BD *Candida auris* isolates.

File S6: Anti-fungal strips, agar, and media used in this study with reference number and lot number.

REFERENCES

1. Muñoz, J.F., et al., *Genomic insights into multidrug-resistance, mating and virulence in Candida auris and related emerging species.* Nature communications, 2018. **9**(1): p. 5346.
2. Satoh, K., et al., *Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital.* Microbiology and immunology, 2009. **53**(1): p. 41-44.
3. Spruijtenburg, B., et al., *Confirmation of fifth Candida auris clade by whole genome sequencing.* Emerging Microbes & Infections, 2022. **11**(1): p. 2405-2411.

402 4. Chowdhary, A., et al., *Multidrug-resistant Candida auris infections in critically ill*
403 *coronavirus disease patients, India, April–July 2020.* Emerging infectious diseases,
404 2020. **26**(11): p. 2694.
405 5. Osei Sekyere, J., *Candida auris: A systematic review and meta-analysis of current*
406 *updates on an emerging multidrug-resistant pathogen.* Microbiologyopen, 2018. **7**(4):
407 p. e00578.
408 6. Lockhart, S.R., M.M. Lyman, and D.J. Sexton, *Tools for detecting a "superbug": updates*
409 *on Candida auris testing.* Journal of Clinical Microbiology, 2022. **60**(5): p. e00808-21.
410 7. Lockhart, S.R., et al., *Simultaneous emergence of multidrug-resistant Candida auris on*
411 *3 continents confirmed by whole-genome sequencing and epidemiological analyses.*
412 Clinical Infectious Diseases, 2017. **64**(2): p. 134-140.
413 8. Chow, N.A., et al., *Tracing the evolutionary history and global expansion of Candida*
414 *auris using population genomic analyses.* MBio, 2020. **11**(2): p. 10.1128/mbio. 03364-
415 19.
416 9. Forsberg, K., et al., *Candida auris: The recent emergence of a multidrug-resistant*
417 *fungal pathogen.* Medical mycology, 2019. **57**(1): p. 1-12.
418 10. Sharma, C., et al., *Whole genome sequencing of emerging multidrug resistant Candida*
419 *auris isolates in India demonstrates low genetic variation.* New microbes and new
420 infections, 2016. **13**: p. 77-82.
421 11. Rhodes, J., et al., *Genomic epidemiology of the UK outbreak of the emerging human*
422 *fungal pathogen Candida auris.* Emerging microbes & infections, 2018. **7**(1): p. 1-12.
423 12. Chow, N.A., et al., *Multiple introductions and subsequent transmission of multidrug-*
424 *resistant Candida auris in the USA: a molecular epidemiological survey.* The Lancet
425 Infectious Diseases, 2018. **18**(12): p. 1377-1384.
426 13. Lockhart, S.R., A. Chowdhary, and J.A. Gold, *The rapid emergence of antifungal-*
427 *resistant human-pathogenic fungi.* Nature Reviews Microbiology, 2023: p. 1-15.
428 14. Maphanga, T.G., et al., *In vitro antifungal resistance of Candida auris isolates from*
429 *bloodstream infections, South Africa.* Antimicrobial agents and chemotherapy, 2021.
430 **65**(9): p. 10.1128/aac. 00517-21.
431 15. Armaki, M.T., et al., *First fluconazole-resistant Candida auris isolated from fungal otitis*
432 *in Iran.* Current medical mycology, 2021. **7**(1): p. 51.
433 16. Safari, F., et al., *A chronic autochthonous fifth clade case of Candida auris otomycosis*
434 *in Iran.* Mycopathologia, 2022. **187**(1): p. 121-127.
435 17. Mhlanga, M., et al., *Multilocus sequence typing of azole-resistant Candida auris strains,*
436 *South Africa.* Southern African Journal of Infectious Diseases, 2020. **35**(1): p. 1-7.
437 18. Chowdhary, A., et al., *A multicentre study of antifungal susceptibility patterns among*
438 *350 Candida auris isolates (2009–17) in India: role of the ERG11 and FKS1 genes in*
439 *azole and echinocandin resistance.* Journal of Antimicrobial Chemotherapy, 2018.
440 **73**(4): p. 891-899.
441 19. Berkow, E.L., D. Angulo, and S.R. Lockhart, *In vitro activity of a novel glucan synthase*
442 *inhibitor, SCY-078, against clinical isolates of Candida auris.* Antimicrobial agents and
443 chemotherapy, 2017. **61**(7).
444 20. Jacobs, S.E., et al., *Candida auris pan-drug-resistant to four classes of antifungal*
445 *agents.* Antimicrobial Agents and Chemotherapy, 2022. **66**(7): p. e00053-22.
446 21. Kordalewska, M., et al., *Understanding echinocandin resistance in the emerging*
447 *pathogen Candida auris.* Antimicrobial agents and chemotherapy, 2018. **62**(6): p.
448 10.1128/aac. 00238-18.

22. Escandón, P., et al., *Molecular epidemiology of Candida auris in Colombia reveals a highly related, countrywide colonization with regional patterns in amphotericin B resistance.* Clinical Infectious Diseases, 2019. **68**(1): p. 15-21.
23. Gugnani, H.C., et al., *Burden of serious fungal infections in Bangladesh.* European Journal of Clinical Microbiology & Infectious Diseases, 2017. **36**: p. 993-997.
24. Islam, M.T., et al., *Emergence of wheat blast in Bangladesh was caused by a South American lineage of Magnaporthe oryzae.* BMC biology, 2016. **14**(1): p. 1-11.
25. Fisher, M.C., et al., *Threats posed by the fungal kingdom to humans, wildlife, and agriculture.* MBio, 2020. **11**(3): p. 10.1128/mbio. 00449-20.
26. Chowdhary, A., et al., *Multidrug-resistant endemic clonal strain of Candida auris in India.* European journal of clinical microbiology & infectious diseases, 2014. **33**: p. 919-926.
27. Clancy, C.J. and M.H. Nguyen, *Emergence of Candida auris: an international call to arms*. 2017, Oxford University Press US. p. 141-143.
28. Dutta, S., et al., *Detection of Candida auris and its antifungal susceptibility: first report from Bangladesh.* IMC Journal of Medical Science, 2019. **13**(2): p. 18-22.
29. Sathi, F.A., et al., *Prevalence and antifungal susceptibility of clinically relevant candida species, identification of candida auris and kodamaea ohmeri in Bangladesh.* Tropical Medicine and Infectious Disease, 2022. **7**(9): p. 211.
30. Tan, Y.E., et al., *Candida auris in Singapore: Genomic epidemiology, antifungal drug resistance, and identification using the updated 8.01 VITEK® 2 system.* International journal of antimicrobial agents, 2019. **54**(6): p. 709-715.
31. Suphavilai, C., et al., *Discovery of the sixth Candida auris clade in Singapore.* medRxiv, 2023: p. 2023.08. 01.23293435.
32. Roberts, S.C., et al., *Genetic evaluation of nosocomial Candida auris transmission.* Journal of clinical microbiology, 2021. **59**(4): p. 10.1128/jcm. 02252-20.
33. Bagal, U.R., et al., *MycoSNP: a portable workflow for performing whole-genome sequencing analysis of Candida auris*, in *Candida auris: Methods and Protocols*. 2022, Springer. p. 215-228.
34. Li, H., *Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM.* arXiv preprint arXiv:1303.3997, 2013.
35. McKenna, A., et al., *The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data.* Genome research, 2010. **20**(9): p. 1297-1303.
36. Stamatakis, A., *RAxML version 8: a tool for phylogenetic analysis and post-analysis of large phylogenies.* Bioinformatics, 2014. **30**(9): p. 1312-1313.
37. Letunic, I. and P. Bork, *Interactive Tree Of Life (iTOL) v5: an online tool for phylogenetic tree display and annotation.* Nucleic acids research, 2021. **49**(W1): p. W293-W296.
38. Bankevich, A., et al., *SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing.* Journal of computational biology, 2012. **19**(5): p. 455-477.
39. Gurevich, A., et al., *QUAST: quality assessment tool for genome assemblies.* Bioinformatics, 2013. **29**(8): p. 1072-1075.
40. Rybak, J.M., et al., *In vivo emergence of high-level resistance during treatment reveals the first identified mechanism of amphotericin B resistance in Candida auris.* Clinical Microbiology and Infection, 2022. **28**(6): p. 838-843.
41. *Clinical and Laboratory Standards Institute (2008) Reference method for broth dilution antifungal susceptibility testing of yeasts, 3rd ed. Approved standard. CLSI document*

496 *M27-A3. Clinical and Laboratory Standards Institute, Wayne*. 2008; 3rd:[Available
497 from: https://clsi.org/media/1461/m27a3_sample.pdf.
498 42. CDC. *Candida auris Antifungal Susceptibility Testing*. 2020; Available from:
499 https://www.cdc.gov/fungal/candida-auris/c-auris-antifungal.html
500 43. CLSI, *Performance standards for antifungal susceptibility testing of yeasts*. 2017,
501 Clinical and Laboratory Standards Wayne, PA.
502 44. Xie, O., et al., *Candida duobushaemulonii sepsis and Candida auris co-isolation*
503 *following hospitalisation in Vietnam.* Pathology, 2020. **52**(5): p. 590-591.
504 45. Siopi, M., et al., *Evaluation of the Vitek 2 system for antifungal susceptibility testing of*
505 *Candida auris using a representative international panel of clinical isolates:*
506 *overestimation of amphotericin B resistance and underestimation of fluconazole*
507 *resistance.* Journal of Clinical Microbiology, 2024: p. e01528-23.
508

TABLE 1: Patient metadata of sequenced *Candida auris* isolates.

Sample ID	Clade	Patient Age Range (Years)	Collection Source	Collection Date (Year)	Travel History	Colonization Type
101019	Clade I	56-60	ICU	2021	No	HAI
101008	Clade I	41-45	ICU	2021	No	HAI
101009	Clade I	31-35	ICU	2021	No	HAI
101022	Clade I	31-35	ICU	2021	UAE	HAI
101077	Clade I	11-15	ICU	2021	No	On admission
101082	Clade I	21-25	ICU	2021	No	On admission
101101	Clade I	51-55	ICU	2021	No	On admission
101087	Clade I	16-20	ICU	2021	No	On admission
102096	Clade VI	0-5	NICU	2021	No	On admission
102170	Clade VI	0-5	NICU	2021	No	On admission

*HAI = Hospital acquired infection.

TABLE 2: Phenotypic differences observed between BD Clade I and Clade VI isolates of *Candida auris* at different timelines (A) 24 hours (B) 48 hours and (C) 72 hours.

Hour	Colony Characteristics	Clade I	Clade VI	Comments
24	Size	Tiny	Large	Difference in colony morphology
	Morphology	Mated	Isolated	
	Color	Whitish	Whitish Blue	
48	Size	Medium Mucoid	Large Mucoid	Difference in colony size and color
	Morphology	Isolated	Single Isolated	
	Color	Whitish	Whitish Blue	
72	Size	Large Mucoid	Large Mucoid	Both Clades show similar characteristics
	Morphology	Single Isolated	Single Isolated	
	Color	Whitish Blue	Whitish Blue	

TABLE 3: Results of known mutation analysis and antifungal susceptibility test for azoles, polyenes, and echinocandins.

Sample ID	Clade	Azole		Echinocandin	Polyene	Gene Mutations	
		Fluconazole	Voriconazole	Caspofungin	Amphotericin B	*ERG11*	*FCY1*
101019	Clade I	256	32	0.19	1	Y132F	S70R
101008	Clade I	256	32	0.25	1	Y132F	S70R
101009	Clade I	256	32	0.38	1	Y132F	S70R
101022	Clade I	256	32	0.125	2	Y132F	S70R
101077	Clade I	256	32	0.25	0.5	Y132F	S70R
101082	Clade I	256	32	0.19	0.75	Y132F	S70R
101101	Clade I	256	32	0.25	0.5	Y132F	S70R
101087	Clade I	256	32	0.25	1	Y132F	S70R
102096	Clade VI	6	0.19	0.125	0.75	-	-
102170	Clade VI	8	0.19	0.125	2	-	-

TABLE 4: Results of 5-flucytosine antifungal susceptibility test by disk diffusion and VITEK®2 method.

Sample ID	Clade	Disk Diffusion		VITEK®2		Gene Mutation
		ZOD (mm)	Resistance Profile	MIC (mg/L)	Resistance Profile	*FCY1*
101019	Clade I	6	R	≥ 64	R	S70R
101008	Clade I	36	S	≤ 1	S	S70R
101009	Clade I	30	S	≤ 1	S	S70R
101022	Clade I	35	S	≤ 1	S	S70R
101077	Clade I	34	S	≤ 1	S	S70R
101082	Clade I	34	S	≤ 1	S	S70R
101101	Clade I	30	S	≤ 1	S	S70R
101087	Clade I	33	S	≤ 1	S	S70R
102096	Clade VI	32	S	≤ 1	S	-
102170	Clade VI	31	S	≤ 1	S	-

*S = Susceptible, I = Intermediate, R = Resistant. The categorization of resistance was based on established clinical breakpoints provided by CLSI.


A.
Country
Bangladesh
Canada
Colombia
India
Iran
Israel
Japan
Kenya
Pakistan
Panama
South Africa
South Korea
Spain
UAE
UK
USA
Venezuela
Clades
Clade I (South Asian)
Clade II (East Asian)
Clade III (African)
Clade IV (South American)
Clade V (Iranian)
Clade VI
Clades
Country
B11205
India B11207
Pakistan B11116
USA NJ B11858
UK 15B5
101019
UAE B14000
101022
101087
101077
101009
101008
101101
101082
USA IN B12631
Spain AA-200
South Africa B11221
USA FL B18833
Kenya B16419
Canada B13463
USA NY B12043
USA FL B14308
Japan B11220
South Korea B11808
Iran IRFC 4050
Iran TMML616
Iran TMML617
Iran MRL40
Iran IFRC2087
102096
102170
Venezuela B11243
Israel B11896
Panama B12107
Colombia B12279
USA IL B11842
Tree scale: 0.1
B.
19533
21038
102096
102170
Venezuela B11243
Israel B11896
Panama B12107
Colombia B12279
USA ILB11842
Clades
Country
C.
Iran_IFRC2087
Iran_IRFC_4050
Iran_MRL40
Iran_TMML616
Iran_TMML617
102096
102170
Panama_B12107
Israel_B11896
USA_IL_B11842
Colombia_B12279
Venezuela_B11243
Canada_B13463
USA_NY_B12043
USA_FL_B14308
Japan_B11220
South_Korea_B11808
USA_NJ_B11858
Pakistan_B 11116
reference
India_B 11207
UK_15B5
101077
101009
101101
101087
101082
101008
101019
101022
UAE_B14000
Spain_AA-200
USA_FL_B18833
USA_IN_B12631
Kenya_B16419
South_Af rica_B 11221
250000
200000
150000
100000
50000
0